Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 2

1(33.3%)

3Total

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06830135Not ApplicableNot Yet Recruiting

Telehealth Approach to Enhancing Glycemic Control

Role: lead

NCT02206360Active Not Recruiting

Pancreatic Cancer Early Detection Program

Role: lead

NCT05947708Not ApplicableCompleted

The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300

Role: collaborator

NCT03971201Phase 2Unknown

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

Role: lead

NCT04293211Completed

Effectiveness of the Adding High Fidelity Simulation to the Bleeding Control Course in Regards to Proper Tourniquet Placement Amongst School Personnel

Role: lead

All 5 trials loaded